IFNG and cancer: Upon CD8+ T cell activation, released IFN-γ binds its receptors and activates the JAK/STAT signaling pathway, leading to IRF-1 activation and induction of PD-L1 expression on tumor cells, as reported in various human cancer models [53,54,55].